Interní Med. 2005; 7(3): 115-119

Pharmacotherapy Tachyarrhythmias

prof. MUDr. Jan Lukl CSc
I. interní klinika FN a LF UP Olomouc

Although radiofrequency catheter ablations has evolved increasingly and represent an effective causal modality of treatment of supraventricular tachycardias, antiarrhythmic drugs still remain a basis for acute and chronic pharmacological treatment. In everyday clinical practise it is usefull to classify antiarrhythmics according to their properties as 1/ AV node blocking agents, slowing the conduction through the AV node, and 2/ stabilizing agents that effectively stabilize electrical events in the artria, accessory pathways and in the ventricles. A new classification of tachyarrhythmias into four groups according to their regularity, frequency, and QRS width is discussed in the current article. Appropriate therapeutical action in each group of arrhythmias is also stated.

Keywords: Key words: tachyarrhythmias, therapy, antiarrhythmic drugs, anticoagulation.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lukl J. Pharmacotherapy Tachyarrhythmias. Interní Med. 2005;7(3):115-119.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Shah BR, Russo A, Kuntz C, et al. Changing patterns in antiarrhythmic drugs use in implantable cardioverter defibrillator patients over the last decade. PACE 2001; 24: 649.
    2. Vaughan Williams EM. Significance of classifying antiarrhythmic action since the Cardiac Arrhythmia Supression Trial. J Clin Pharmacol 1991; 31: 123-135. Go to original source... Go to PubMed...
    3. Schwartz PJ, Zaza A. The Sicilian Gambit revisted - theory and practice. Eur Heart J 1992; 13: 23-29. Go to original source... Go to PubMed...
    4. Braunwald E, Zipes DP, Libby P. Heart disease. WB Sounders comp (eds). Philadelphia, USA, 2001: p 729.
    5. Buxton AE, Marchlinski FE, Doherty JU: Hazards of intravenous verapamil for sustained ventricular tachycardia. Am J Cardiol, 1987; 59: 1107. Go to original source... Go to PubMed...
    6. Laupacis A, Albers G, Dunn M, et al. Antithrombotic therapy in atrial fibrillation. Chest 1992; 102 (Suppl 4): 426S-433S. Go to original source... Go to PubMed...
    7. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFIRM) investigators. A comparison of rate control and rhythm control in patients with recurrent atrial fibrillation. N Engl J Med 2002; 347: 1825-1833. Go to original source... Go to PubMed...
    8. Brignole M, Menozzi C. Control of rapid heart rate in patients with atrial fibrillation: drug or ablation? PACE 1996; 18: 348-356. Go to original source... Go to PubMed...
    9. Mayer O. Ximelagatran (Exanta) - nové antikoagulans v léčbě fibrilace síní. Cor Vasa 2004; 46: 582-586.
    10. Anderson JL, Hallstrom AP, Epstein AE, et al. Design and results of the Antiarrhythmics vs Implantable Defibrillators (AVID) registry. Circulation 1999; 99: 1692-1699. Go to original source... Go to PubMed...
    11. Táborský M. Zásady pro implantace kardiostimulátorů a implantabilních kardioverterů-defibrilátorů pracovní skupiny pro arytmie a kardiostimulaci České kardiologické společnosti. Cor Vasa 2002; 43: K32-K41.
    12. Nguyen PT, Scheinman MM, Seger J. Polymorphous ventricular tachycardia: clinical characterization, therapy, and the QT interval. Circulation 1986; 74: 340-349. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.